The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis

Hemodialysis International

Volumn 13, Issue 1, 2009, Pages 43-47

  Sombolos, Kostas I ^a   Fragia, Theodora K ^b   Gionanlis, Lazaros C ^a   Veneti, Panagiota E ^a   Bamichas, Gerasimos I ^a   Fragidis, Stelios K ^a   Georgoulis, Ioannis E ^b   Natse, Taïsir A ^a  

^a Renal Unit   (Greece)

^b Hematology Laboratory   (Greece)

Author keywords

Enoxaparin; Hemodiafiltration; Hemodialysis; On line

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEMOGLOBIN; NITROGEN; POLYESTER; POLYSULFONE; UREA;

ADULT; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; ONLINE SYSTEM; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FEMALE; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RENAL DIALYSIS; UREA;

EID: 59249102764     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00336.x     Document Type: Article

References (15)

1. Christidou FN, Frangia TK, Bamichas GI, et al. Comparison of two low-molecular weight heparins (LMWHs) tinzaparin and bemiparin, during hemodialysis. Int J Clin Pharmacol Ther. 2005; 43:335-338.
2. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(Suppl):64S-94S.
3. Lai KN, Wang AYM, Ho K, Szeto CC, Wong LKS, Yu AWY. Use of low-molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996; 28:721-726.
4. Amanzadeh J, Reilly R. Heparin clearance during continuous veno-venous hemofiltration. Intens Care Med. 1994; 20:212-215.
5. McMahon LP, Chester K, Walker RG. Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. Am J Kidney Dis. 2004; 44:509-516.
6. Isla A, Gascon AR, Maynar J, et al. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther. 2005; 27:1444-1451.
7. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol. 1993; 4:1205-1213.
8. Ronco C, Canaud B, Aljama P. Hemodiafiltration. Contrib Nephrol. 2007; 158:110-122.
9. Enoxaparin. Available from: http://en.wikipedia.org/wiki (accessed date: May 15, 2008).
10. Grau E, Siguenza F, Maduell F, et al. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron. 1992; 62:13-17.
11. Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant. 2003; 18:2348-2353.
12. Renaux J, Thomas M, Crost T, Loughraier N, Vantard G. Activation of the kallikrein-kinin system in hemodialysis: Role of membrane electronegativity, blood dilution and pH. Kidney Int. 1999; 55:1097-1103.
13. Eleftheriadis Th, Antoniadi G, Liakopoulos V, Tsiandoulas A, Barboutis K, Stefanidis I. Propyl gallate-induced platelet aggregation in patients with end-stage renal disease: The influence of the haemodialysis procedure. Nephrology. 2006; 11:3-8.
14. Matata BM, Courtney JM, Sundaram S, et al. Determination of contact phase activation by the measurement of the activity of supernatant and membrane surface-adsorbed factor XII (FXII): Its relevance as a useful parameter for the in vitro assessment of haemodialysis membranes. J Biomed Mater Res. 1996; 31:63-70.
15. Sombolos K, Fragia K, Gionanlis l, et al. Use of fondaparinux as an anticoagulant during hemodialysis: A preliminary study. Int J Clin Pharmacol Ther. 2008; 46:198-203.